Sky Chemi-Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 2294.48%
- Profit Growth 861.54%
- Ebitda -89.53%
- Net Worth 30.36%
- Total Assets 1.91%
About Sky Chemi-Pharma
Sky Chemi-Pharma Private Limited (SCPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 August 2014 and has a history of Ten years and five months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Adesh Saple, Adnya Saple, and Sharad Agarwal serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U33119MH2014PTC257599
-
Company No.
257599
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 Aug 2014
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Sky Chemi-Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Adesh Saple
|
Director | 26-Aug-2014 | Current |
|
Adnya Saple
|
Director | 01-Mar-2021 | Current |
|
Sharad Agarwal
|
Director | 01-Mar-2021 | Current |
Financial Performance of Sky Chemi-Pharma.
Sky Chemi-Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 2294.48% increase. The company also saw a substantial improvement in profitability, with a 861.54% increase in profit. The company's net worth Soared by an impressive increase of 30.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sky Chemi-Pharma?
In 2020, Sky Chemi-Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sky Touch Aviation Private LimitedAdesh Saple and Sharad Agarwal are mutual person
-
Aslesha Buildcon Private LimitedAdesh Saple and Sharad Agarwal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sky Chemi-Pharma?
Unlock and access historical data on people associated with Sky Chemi-Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sky Chemi-Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sky Chemi-Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
